Pfizer Inc banner

Pfizer Inc
SGO:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
SGO:PFE
Watchlist
Price: 49.19 USD -0.36% Market Closed
Market Cap: $165.2B

Gross Margin

75.8%
Current
Improving
by 3.3%
vs 3-y average of 72.5%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
75.8%
=
Gross Profit
$47.4B
/
Revenue
$62.6B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
75.8%
=
Gross Profit
$47.4B
/
Revenue
$62.6B

Peer Comparison

Country Company Market Cap Gross
Margin
US
Pfizer Inc
NYSE:PFE
156.9B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
987.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
596.5B USD
Loading...
US
Abbvie Inc
NYSE:ABBV
407.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
293B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
240.5B GBP
Loading...
US
Merck & Co Inc
NYSE:MRK
307.4B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
UK
GSK plc
XETRA:GS71
101B EUR
Loading...
FR
Sanofi SA
PAR:SAN
99.2B EUR
Loading...
AU
CSL Ltd
ASX:CSL
71.1B AUD
Loading...

Market Distribution

Higher than 85% of companies in the United States of America
Percentile
85th
Based on 12 729 companies
85th percentile
75.8%
Low
-24 813% — 28.9%
Typical Range
28.9% — 60.5%
High
60.5% — 10 905 714.3%
Distribution Statistics
the United States of America
Min -24 813%
30th Percentile 28.9%
Median 43%
70th Percentile 60.5%
Max 10 905 714.3%

Pfizer Inc
Glance View

Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.

PFE Intrinsic Value
HIDDEN
Show
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
75.8%
=
Gross Profit
$47.4B
/
Revenue
$62.6B
What is Pfizer Inc's current Gross Margin?

The current Gross Margin for Pfizer Inc is 75.8%, which is above its 3-year median of 72.5%.

How has Gross Margin changed over time?

Over the last 3 years, Pfizer Inc’s Gross Margin has increased from 66.3% to 75.8%. During this period, it reached a low of 62.6% on Oct 1, 2023 and a high of 80.6% on Sep 29, 2024.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett